American journal of ophthalmology · 2026
Two-Year Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Clinical Practice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Mengxi, Lam Winston Z, Berni Alessandro, Herrera Gissel, El-Mulki Omar S, Badla Omar, Herrera Eduardo, Liu Jeremy, Cheng Yuxuan, Kastner James, Trivizki Omer, Meng Da, Patel Pratik, Kumar Sivathanu, Zhang Yi, Le Viet Hoan, O'Brien Robert C, Nicola Maura Di, Yehoshua Zohar, Dubovy Sander R, Wang Ruikang K, Gregori Giovanni, Rosenfeld Philip J
Аннотация
PURPOSE: To report the 2-year experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD).
DESIGN: Retrospective interventional case series.
METHODS: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study. All eyes underwent SS-OCTA imaging before and during pegcetacoplan therapy to assess for GA lesion size, the presence of non-exudative macular neovascularization (MNV), and the onset of exudation. The growth rate of GA and best-corrected visual acuity (BCVA) were assessed for all eyes treated for 2 years.
RESULTS: From April 12, 2023 to December 8, 2025, 77 eyes from 58 patients continued pegcetacoplan treatment for 2 years. Eyes received an average of 18±3 injections with an interval of 1.3 months between injections. For the 72 eyes with 2 years of follow-up and measurable GA, the square-root (sqrt) GA growth rate after pegcetacoplan treatment was 0.22±0.12 mm/year. Of the 72 eyes, 71 eyes either decreased further in their sqrt GA growth rate or remained the same in the second year, while 1 eye had an increase in the sqrt GA growth rate. This eye also received concomitant anti-VEGF therapy due to exudative MNV. Of these 72 eyes, 49 eyes had prior annual visits before treatment. In these eyes, the annual sqrt GA growth rate was 0.33±0.21 mm/year before pegcetacoplan and 0.19±0.11 mm/year after 2 years, resulting in a 41% decrease in the growth rate (p<0.001). There were no significant differences in GA growth rates between foveal and non-foveal GA (all p≥0.99). The mean BCVA declined from 63±14 to 55±16 letters over 2 years (p<0.001), with no significant difference between foveal and non-foveal GA (p=0.14). Positive correlations were found between the sqrt GA growth rates prior to treatment and the percent growth inhibition over both 1 year (r=0.33, p=0.02) and 2 years of treatment (r=0.40, p=0.007).
CONCLUSIONS: Pegcetacoplan therapy reduced the growth rate of GA by about 41% over 2 years and continued to show accumulated efficacy during the second year.
DESIGN: Retrospective interventional case series.
METHODS: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study. All eyes underwent SS-OCTA imaging before and during pegcetacoplan therapy to assess for GA lesion size, the presence of non-exudative macular neovascularization (MNV), and the onset of exudation. The growth rate of GA and best-corrected visual acuity (BCVA) were assessed for all eyes treated for 2 years.
RESULTS: From April 12, 2023 to December 8, 2025, 77 eyes from 58 patients continued pegcetacoplan treatment for 2 years. Eyes received an average of 18±3 injections with an interval of 1.3 months between injections. For the 72 eyes with 2 years of follow-up and measurable GA, the square-root (sqrt) GA growth rate after pegcetacoplan treatment was 0.22±0.12 mm/year. Of the 72 eyes, 71 eyes either decreased further in their sqrt GA growth rate or remained the same in the second year, while 1 eye had an increase in the sqrt GA growth rate. This eye also received concomitant anti-VEGF therapy due to exudative MNV. Of these 72 eyes, 49 eyes had prior annual visits before treatment. In these eyes, the annual sqrt GA growth rate was 0.33±0.21 mm/year before pegcetacoplan and 0.19±0.11 mm/year after 2 years, resulting in a 41% decrease in the growth rate (p<0.001). There were no significant differences in GA growth rates between foveal and non-foveal GA (all p≥0.99). The mean BCVA declined from 63±14 to 55±16 letters over 2 years (p<0.001), with no significant difference between foveal and non-foveal GA (p=0.14). Positive correlations were found between the sqrt GA growth rates prior to treatment and the percent growth inhibition over both 1 year (r=0.33, p=0.02) and 2 years of treatment (r=0.40, p=0.007).
CONCLUSIONS: Pegcetacoplan therapy reduced the growth rate of GA by about 41% over 2 years and continued to show accumulated efficacy during the second year.